Navigation Links
Valeant to Acquire Polish Dermatology Company
Date:5/8/2009

ALISO VIEJO, Calif., May 8 /PRNewswire-FirstCall/ -- Valeant Pharmaceuticals International (NYSE: VRX) announced that it has acquired EMO-FARM Ltd., a privately held company located in Poland for approximately $28 million. The transaction expands the base for Valeant in Poland into multiple therapeutic categories. EMO-FARM has a strong expertise in topical products and brings with it a portfolio of currently marketed products and additional products under registration. As part of the transaction, Valeant will also acquire a state-of-the-art 13,000 square foot manufacturing plant completed earlier this year that specializes in gels, creams and ointments. Current annualized revenues are approximately $12 million.

"The acquisition of EMO-FARM is consistent with our business plan strategy," stated J. Michael Pearson, chairman and chief executive officer. "We now have a platform from which we can launch various topical products including our dermatology pipeline and become a premier dermatology company in the countries in which we operate The combination of an established portfolio of products, an anti-infective topical compound we plan to launch in 2010, and a cGMP-ready plant that equips us with new manufacturing capabilities, provides us with a solid dermatology opportunity in Poland, and eventually, throughout Central Europe."

About Valeant

Valeant Pharmaceuticals International (NYSE: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology and dermatology. More information about Valeant can be found at www.valeant.com.

FORWARD-L
'/>"/>

SOURCE Valeant Pharmaceuticals International
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Valeant Pharmaceuticals to Present at Bank of America and Merrill Lynch 2009 Health Care Conference
2. Valeant Pharmaceuticals Highlights Taribavirin Phase IIb 60-Week Data Presentation at European Association for the Study of Liver (EASL) Annual Meeting
3. Valeant Pharmaceuticals to Announce 2009 First Quarter Results on May 5, 2009
4. Valeant Pharmaceuticals Appoints President of Valeant Pharmaceuticals International
5. Valeant Pharmaceuticals to Present at Cowen and Company 29th Annual Health Care Conference
6. Valeant Pharmaceuticals Announces Annual Stockholder Meeting Date
7. Valeant Pharmaceuticals Reports Fourth Quarter and Full Year Financial Results
8. Valeant Pharmaceuticals to Announce 2008 Fourth Quarter and Year Results on February 24, 2009
9. Three Rivers Pharmaceuticals(R), LLC Acquires Hepatitis C Drug Infergen(R) from Valeant Pharmaceuticals
10. JLL Announces Extension of Its Offer To Acquire Patheon and Take Up of Deposited Restricted Voting Shares
11. Teikoku Pharma USA Acquires Travanti Pharma Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... A unique partnership to support private efforts to provide ... provide a model for similar efforts should federal officials ... of reform of the VA health system, according to ... Veterans Initiative, a joint project of philanthropic groups and ... patient care, education and other services to veterans and ...
(Date:9/18/2014)... NY (PRWEB) September 18, 2014 ItsHot.com, ... NY, is now offering a 65-80% discount on its ... a whopping 71% off on its 14K Gold Pave ... diamond band can now be bought for just $775. ... 406147. , Talking about this diamond band, a representative ...
(Date:9/18/2014)... Pathways Home Health & Hospice has ... Medical Director. Prior to accepting the directorship, Brown ... Pathways KIDS, adult palliative care, and hospice teams that ... Counties. , In her new position, Brown is ... program. She will supervise five medical directors who are ...
(Date:9/18/2014)... HealthDay Reporter THURSDAY, Sept. ... that testosterone replacement therapy effectively treats normally sagging levels of ... Drug Administration advisory panel said Wednesday. The panel, from ... of the popular drugs and require drug makers to conduct ... according to Bloomberg News . "The whole idea ...
(Date:9/18/2014)... (Sept. 17, 2014) -- Two independent groups of ... the University of Kentucky, and Charles Lowenstein, MD, ... studies exploring the role that a gene called ... , According to Whiteheart, previous genome-wide association studies ... factor that regulates a protein called Von Willebrand ...
Breaking Medicine News(10 mins):Health News:Study provides insight about providing private mental health service to veterans 2Health News:Study provides insight about providing private mental health service to veterans 3Health News:ItsHot.com Now Offering 65-80% Discount on its Striking Collection of Diamond Wedding Bands 2Health News:Dr. Ellen Brown Promoted to Chief Medical Director at Pathways Home Health & Hospice 2Health News:FDA Panel: Limit Testosterone Drug Use 2Health News:FDA Panel: Limit Testosterone Drug Use 3Health News:FDA Panel: Limit Testosterone Drug Use 4Health News:University of Kentucky research explores STXBP5 gene and its role in blood clotting 2
... gap is alive and well in heart disease, a new international ... to treatment in both heart attack and severe chest pain. ... twice as likely as men to have normal or mild results ... blockage taking up more than 50 percent of any one blood ...
... ... Flows Increase, BIRMINGHAM, Ala., May 6 HealthSouth,Corporation (NYSE: ... first quarter ended March 31, 2008. Compared to the,first quarter of ... net income increased by $76.4 million., "The results of the ...
... and,Mississippi still working to recover from the Hurricane Katrina ... Department of,Health and Human Services (HHS)., "HHS continues ... health care,problems created by Hurricane Katrina," Secretary Mike Leavitt ... make sure the citizens of these,states have continued access ...
... Today at 5:30 p.m. EDT, FRAZER, Pa., ... that a Joint Advisory Committee to the U.S. ... approval of an expanded,label for FENTORA(R) (fentanyl buccal ... opioid-tolerant patients with chronic pain conditions.,The panel expressed ...
... have shown for the first time that thrombopoietin (TPO), ... to increase platelet count in cancer patients during chemotherapy, ... heart attack. , The study, led by ... the division of cardiothoracic surgery, was published in the ...
... now register to attend TCT2008 (Transcatheter Cardiovascular Therapeutics), ... Foundation. TCT gathers leading medical researchers and clinicians ... developments in the field of interventional cardiology and ... state-of-the-art techniques and training to interventional cardiologists around ...
Cached Medicine News:Health News:Women and heart attack: Study finds failure to recognize symptoms, failure to treat appropriately 2Health News:Women and heart attack: Study finds failure to recognize symptoms, failure to treat appropriately 3Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 2Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 3Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 4Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 5Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 6Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 7Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 8Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 9Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 10Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 11Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 12Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 13Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 14Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 15Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 16Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 17Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 18Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 19Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 20Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 21Health News:Hospitals in Louisiana and Mississippi to Receive More Katrina Recovery Grants 2Health News:Cephalon Announces FDA Advisory Committee Recommendation Against Approval of an Expanded Label for FENTORA 2Health News:Cephalon Announces FDA Advisory Committee Recommendation Against Approval of an Expanded Label for FENTORA 3Health News:Cephalon Announces FDA Advisory Committee Recommendation Against Approval of an Expanded Label for FENTORA 4Health News:Cephalon Announces FDA Advisory Committee Recommendation Against Approval of an Expanded Label for FENTORA 5Health News:Cephalon Announces FDA Advisory Committee Recommendation Against Approval of an Expanded Label for FENTORA 6Health News:Naturally-occuring protein may be effective in limiting heart attack injury and restoring function 2Health News:Media registration now open for TCT2008 2
(Date:9/18/2014)... , Sept. 18, 2014  Casen Buswell has a ... muscles to harden.  His case is one of only 14 ... world.  The only hospital in the United States ... world, offering treatment with the dual wave-length laser, is Methodist ... San Antonio . Using a laser available in ...
(Date:9/18/2014)... Sept. 18, 2014  Decision Resources Group finds ... the United States , 54 percent of ... inhibitor Tafinlar for BRAF -mutation-positive unresectable or ... prescribed GlaxoSmithKline,s MEK inhibitor Mekinist. Among current non-prescribers ... percent and 43 percent, respectively) expects to prescribe ...
(Date:9/18/2014)... PLYMOUTH MEETING, Pa. , Sept. 18, 2014 /PRNewswire/ ... of innovative approaches to diagnosing and treating Autism Spectrum ... an Exclusive License Agreement with The Research Foundation for ... this Agreement, Iliad will provide a new biomarker to ... associated with susceptibility to ASD. This biomarker is expected ...
Breaking Medicine Technology:Methodist Children's Hospital In San Antonio, TX Only Hospital In The U.S. Treating Rare Vascular Condition With Dual Wave-Length Laser 2At One Year Post-Launch, Approximately One Half of Surveyed U.S. Medical Oncologists Have Prescribed Single-Agent Tafinlar and Mekinist to Their Malignant Melanoma Patients 2Iliad Neurosciences, Inc. enters into an Exclusive License Agreement with The Research Foundation for The State University of New York 2Iliad Neurosciences, Inc. enters into an Exclusive License Agreement with The Research Foundation for The State University of New York 3
... , COLLEGE STATION, ... , MD, FACS, of The Texas Institute for Thyroid and Parathyroid ... College Station Medical Center in College Station, Texas . ... in North America to be recognized by Intuitive Surgical ...
... , Jan. 14 In the keynote address at ... Lechleiter , Ph.D., chairman and CEO of Eli Lilly and Company, ... edge in innovation and improving our focus on medical innovation,s richest ... in the coming decade.  His speech focused on bioscience innovation, a ...
Cached Medicine Technology:Milestone Achieved in Revolutionary Robotic Thyroid Surgery 2Lilly CEO Stresses Human Element in Driving Medical Innovation 2Lilly CEO Stresses Human Element in Driving Medical Innovation 3
Inquire...
... Novas Point-of-Care Manager is ... gas and critical care ... the industry. PDM ... workstation designed to effortlessly ...
... The ISI Micro Nest is the wall-mounted organizer ... a variety of sizes and diameters. The Micro ... the right brush for the cleaning task. These ... specifically for those hard-to-clean instruments such as cannulas. ...
... is the non-silicone lubricant designed to "spot" ... lubricates sticky pivot points, hinges, box joints ... allows you to lubricate with precision. Safe ... Ideal for carts, hinges, medical equipment, and ...
Medicine Products: